Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma
The loss of CD47 on aging cells serves as a signal to macrophages to eliminate the target. Therefore, CD47 is a “do-not-eat-me” sign preventing macrophagal phagocytosis via interaction with its ligand SIRPα. Malignant lymphocytes of mycosis fungoides and Sézary syndrome express CD47 highly, thus, be...
Main Authors: | Amy Xiao, Oleg E. Akilov |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-11-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/11/22/3591 |
Similar Items
-
Overcoming immunotherapeutic resistance in PDAC: SIRPα-CD47 blockade
by: Abdullahi Alausa, et al.
Published: (2022-07-01) -
Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy
by: Pengcheng Zhao, et al.
Published: (2024-01-01) -
Deciphering the role of CD47 in cancer immunotherapy
by: Yu'e Liu, et al.
Published: (2024-09-01) -
Therapeutic strategies targeting CD47-SIRPα signaling pathway in gastrointestinal cancers treatment
by: Zhengping Che, et al.
Published: (2025-01-01) -
Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives
by: Chenyang Jiang, et al.
Published: (2024-07-01)